Another study conducted by Flanagan et al. involved a randomized, placebo-controlled, double-blind design and demonstrated lower PTSD symptoms and depression following long-term exposure therapy with weekly oxytocin doses in affected patients [214]. The gene discussed is OXT; the disease is depressive symptom measurement.